title: Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial.
abstract: BACKGROUND
  Optimal anti-Helicobacter pylori treatment has not yet been established.
  
  
  OBJECTIVE
  To evaluate H. pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy in northeastern of Brazil.
  
  
  METHODS
  One hundred and four patients with H. pylori infection, as determined by rapid urease testing and histology, were randomly assigned to receive either: lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF; n = 52); or lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz; n = 52). H. pylori eradication was assessed 3 months following completion of therapy by means of rapid urease testing, histology and a 14C-urea breath test.
  
  
  RESULTS
  H. pylori eradication was achieved in 46 of 52 (88.4%, 95% CI: 77.5%-95.1%) patients in LTF group and in 14 of 52 (26.9%, 95% CI: 16.2%-40,1%) patients in LAAz group. On a per-protocol analysis, eradication rates were 91.8% (95% CI: 81.4%-97.3%) and 28.5% (95% CI: 17.2%-42.3%), respectively in LTF and LAAz groups.
  
  
  CONCLUSIONS
  The LAAz regimen yielded unacceptably low eradication rates. On the other hand, the LTF scheme represents a suitable alternative for H. pylori eradication.
authors.affiliation: Department of Internal Medicina, Federal University of Ceará, Walter Cantídeo University Hospital, Fortaleza, CE, Bazil.
authors.forename: Laura Cidrão
authors.initials: LC
authors.lastname: Frota
authors.forename: Maria do Perpétuo Socorro Saldanha
authors.initials: Mdo P
authors.lastname: da Cunha
authors.forename: Carlos René Lima
authors.initials: CR
authors.lastname: Luz
authors.forename: Antonio Haroldo
authors.initials: AH
authors.lastname: de Araujo-Filho
authors.forename: Luciano A S
authors.initials: LA
authors.lastname: Frota
authors.forename: Lucia Libanez Bessa Campelo
authors.initials: LL
authors.lastname: Braga
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D005664:Furazolidone; D000658:Amoxicillin; D017963:Azithromycin; D013752:Tetracycline; D009853:Omeprazole